Novo Nordisk has been actively pursuing licensing deals over the past six months. There are other good reasons to consider ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

Landmark investments, portfolio progress, and expanded presence positionNovo Holdings for long-term growth and impact in Asia SINGAPORE, June 18, 2025 ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.

Telehealth firm 9amHealth has partnered with billionaire entrepreneur Mark Cuban's Cost Plus Drug Company to offer U.S.

'Ozempic Penis' is the new side-effect that people have been turning their heads at, and users are reporting experiencing ...

In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity ...

Indian pharmaceutical companies are gearing up to launch cost-effective versions of the weight-loss and diabetes drug, semaglutide, post patent expiry in 2026.